1887
Rapid communication Open Access
Like 0

Abstract

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.28.2001260
2020-07-16
2020-08-11
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.28.2001260
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/28/eurosurv-25-28-1.html?itemId=/content/10.2807/1560-7917.ES.2020.25.28.2001260&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. [Accessed 10 Jun 2020]. Geneva: WHO. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44.  https://doi.org/10.1038/s41564-020-0695-z  PMID: 32123347 
  3. An EU programme of COVID-19 convalescent plasma collection and transfusion Guidance on collection, testing, processing, storage, distribution and monitored use. [Accessed 12 Jun 2020]. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf
  4. Recommendations for Investigations COVID-19 Convalescent Plasma recommendation. 1 May 2020. [Accessed 12 Jun 2020]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
  5. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-6.  https://doi.org/10.1073/pnas.2004168117  PMID: 32253318 
  6. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582-9.  https://doi.org/10.1001/jama.2020.4783  PMID: 32219428 
  7. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.  https://doi.org/10.1016/j.autrev.2020.102554  PMID: 32380316 
  8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.  https://doi.org/10.1038/s41591-020-0897-1  PMID: 32350462 
  9. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;ciaa310.  https://doi.org/10.1093/cid/ciaa310  PMID: 32198501 
  10. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344.  https://doi.org/10.1093/cid/ciaa344  PMID: 32221519 
  11. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1.full.pdf
  12. Wang X, Guo X, Xin Q, Pan Y, Li j, Chu Y, et al. Neutralising antibody responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.04.15.20065623v3
  13. Harvala H, Robb M, Watkins N, Ljaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.05.20.20091694v1
  14. Roberts DJ, Miflin G, Estcourt L. Convalescent plasma for COVID-19: Back to the future. Transfus Med. 2020;30(3):174-6.  https://doi.org/10.1111/tme.12700  PMID: 32447783 
  15. Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014;209(7):995-1006.  https://doi.org/10.1093/infdis/jit609  PMID: 24253287 
  16. Jääskeläinen AJ, Kekäläinen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, et al. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Euro Surveill. 2020;25(18):2000603.  https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603  PMID: 32400364 
  17. Brochot E, Demey B, Touze A, Belouzard S, Dubuisson J, Schmit JL, et al. Anti-spike, anti-nucleocapsid and neutralising antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.05.12.20098236v2
  18. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1
  19. Caini S, Bellerba F, Corso F, Díaz-Basabe A, Natoli G, Paget J, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill. 2020;25(23):2000980.  https://doi.org/10.2807/1560-7917.ES.2020.25.23.2000980  PMID: 32553061 
  20. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-88.  https://doi.org/10.3201/eid2607.200841  PMID: 32267220 
/content/10.2807/1560-7917.ES.2020.25.28.2001260
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error